Search

Your search keyword '"Hotte, Sebastien J."' showing total 447 results
Start Over Author "Hotte, Sebastien J."
447 results on '"Hotte, Sebastien J."'

3. Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada

Author

Shayegan, Bobby, Wallis, Christopher J. D., Hamilton, Robert J., Morgan, Scott C., Cagiannos, Ilinas, Basappa, Naveen S., Ferrario, Cristiano., Gotto, Geoffrey T., Fernandes, Ricardo, Roy, Soumyajit, Noonan, Krista L., Niazi, Tamim, Hotte, Sebastien J., Saad, Fred, Hew, Huong, Park-Wyllie, Laura, Chan, Katherine F. Y., and Malone, Shawn

Published
2023
Full Text
View/download PDF

4. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel

Author

Papp, Kim A., Melosky, Barbara, Sehdev, Sandeep, Hotte, Sebastien J., Beecker, Jennifer R., Kirchhof, Mark G., Turchin, Irina, Dutz, Jan P., Gooderham, Melinda J., Gniadecki, Robert, Hong, Chih-ho, Lambert, Jo, Lynde, Charles W., Prajapati, Vimal H., and Vender, Ronald B.

Published
2023
Full Text
View/download PDF

5. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers

Author

Dragomir, Alice, Nazha, Sara, Tanguay, Simon, Breau, Rodney H., Bhindi, Bimal, Rendon, Ricardo A., Kapoor, Anil, Hotte, Sebastien J., Basappa, Naveen, Fairey, Adrian, So, Alan I., Kollmannsberger, Christian, Finelli, Antonio, Hansen, Aaron, Canil, Christina, Heng, Daniel, Lattouf, Jean-Baptiste, Bjarnason, Georg, Power, Nicholas, Pouliot, Frédéric, and Wood, Lori A.

Published
2022
Full Text
View/download PDF

6. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces

Author

Woon, Dixon TS, Chandrasekar, Thenappan, Aaron, Lorne, Basappa, Naveen S, Chi, Kim N, Conter, Henry J, Gotto, Geoffrey, Hotte, Sebastien J, Malone, Shawn, Saad, Fred, Shayegan, Bobby, Park-Wyllie, Laura, and Hamilton, Robert J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prostate Cancer, Urologic Diseases, Good Health and Well Being, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

INTRODUCTION:Treatment using abiraterone acetate plus prednisone, enzalutamide, cabazitaxel, and radium-223 (Ra-223) improves overall survival (OS) and quality of life for patients with metastatic castrate-resistant prostate cancer (mCRPC). Despite their proven benefits, access to these therapies is not equal across Canada. METHODS:We describe provincial differences in access to approved mCRPC therapies. Data sources include the pan-Canadian Oncology Drug Review database, provincial cancer care resources, and correspondence with pharmaceutical companies. RESULTS:Both androgen receptor-axis-targeted therapies (ARATs), abiraterone acetate plus prednisone and enzalutamide, are funded by provinces in the pre-and post-chemotherapy setting, however, sequential ARAT use is not funded. "Sandwich" therapy, where one ARAT is used pre-chemotherapy and a second is used upon progression on chemotherapy, is funded in six provinces: Ontario (ON), Alberta, New Brunswick, Prince Edward Island (PEI), Nova Scotia (NS), and Newfoundland and Labrador. Ra-223 is funded in five provinces: ON, Quebec (QC), British Columbia (BC), Saskatchewan, and Manitoba to varying degrees; ON allows Ra-223 either pre- or post-chemo (not both); QC allows Ra-223 post-chemo unless chemo is not tolerated; BC allows Ra-223 if other life-prolonging mCRPC therapies have been received or ineligible. Cabazitaxel is funded in all provinces post-docetaxel, except QC and PEI. Cabazitaxel is not funded as fist-line treatment for mCPRC or in combination with other agents. In ON, BC, QC, and PEI, cabazitaxel is not funded after progression on an ARAT in the post-chemotherapy setting. CONCLUSIONS:While all provinces have access to docetaxel and ARATs, sandwiching sequential ARATs with docetaxel is funded only in select provinces. Ra-223 and cabazitaxel access is not ubiquitous across Canada. Such inequalities in access to life-prolonging therapies could lead to disparities in survival and quality of life among patients with mCRPC. Further research should quantify interprovincial variation in outcomes and cost that may result from variable access.

Published
2018

7. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

Author

Voon, Pei Jye, Chen, Eric X., Chen, Helen X., Lockhart, Albert C., Sahebjam, Solmaz, Kelly, Karen, Vaishampayan, Ulka N., Subbiah, Vivek, Razak, Albiruni R., Renouf, Daniel J., Hotte, Sebastien J., Singh, Arti, Bedard, Philippe L., Hansen, Aaron R., Ivy, S. Percy, Wang, Lisa, Stayner, Lee-Anne, Siu, Lillian L., and Spreafico, Anna

Published
2022
Full Text
View/download PDF

8. 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

Author

Chi, Kim N., primary, Yip, Steven M., additional, Bauman, Glenn, additional, Probst, Stephan, additional, Emmenegger, Urban, additional, Kollmannsberger, Christian K., additional, Martineau, Patrick, additional, Niazi, Tamim, additional, Pouliot, Frédéric, additional, Rendon, Ricardo, additional, Hotte, Sebastien J., additional, Laidley, David T., additional, and Saad, Fred, additional

Published
2024
Full Text
View/download PDF

9. Supplementary Table S9 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma

Author

Petrylak, Daniel P., primary, Eigl, Bernhard J., primary, George, Saby, primary, Heath, Elisabeth I., primary, Hotte, Sebastien J., primary, Chism, David D., primary, Nabell, Lisle M., primary, Picus, Joel, primary, Cheng, Susanna Y., primary, Appleman, Leonard J., primary, Sonpavde, Guru P., primary, Morgans, Alicia K., primary, Pourhosseini, Pourya, primary, Wu, Ruishan, primary, Standley, Laura, primary, Croitoru, Ruslan, primary, and Yu, Evan Y., primary

Published
2024
Full Text
View/download PDF

10. Supplementary Figure S2 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma

Author

Petrylak, Daniel P., primary, Eigl, Bernhard J., primary, George, Saby, primary, Heath, Elisabeth I., primary, Hotte, Sebastien J., primary, Chism, David D., primary, Nabell, Lisle M., primary, Picus, Joel, primary, Cheng, Susanna Y., primary, Appleman, Leonard J., primary, Sonpavde, Guru P., primary, Morgans, Alicia K., primary, Pourhosseini, Pourya, primary, Wu, Ruishan, primary, Standley, Laura, primary, Croitoru, Ruslan, primary, and Yu, Evan Y., primary

Published
2024
Full Text
View/download PDF

11. Data from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma

Author

Petrylak, Daniel P., primary, Eigl, Bernhard J., primary, George, Saby, primary, Heath, Elisabeth I., primary, Hotte, Sebastien J., primary, Chism, David D., primary, Nabell, Lisle M., primary, Picus, Joel, primary, Cheng, Susanna Y., primary, Appleman, Leonard J., primary, Sonpavde, Guru P., primary, Morgans, Alicia K., primary, Pourhosseini, Pourya, primary, Wu, Ruishan, primary, Standley, Laura, primary, Croitoru, Ruslan, primary, and Yu, Evan Y., primary

Published
2024
Full Text
View/download PDF

13. Addressing controversial areas in the management of advanced prostate cancer in Canada: Areas of consensus and controversy from the third Canadian consensus forum.

Author

Saad, Fred, Hotte, Sebastien J., Noonan, Krista, Malone, Shawn, Morash, Christopher, Niazi, Tamim, Rendon, Ricardo A., Shayegan, Bobby, Basappa, Naveen S., Cagiannos, Ilias, Danielson, Brita, Delouya, Guila, Fernandes, Ricardo, Ferrario, Cristiano, Finelli, Antonio, Gotto, Geoffrey T., Hamilton, Robert J., Izard, Jason P., Kapoor, Anil, and Lalani, Aly-Khan

Subjects
*PROSTATE tumors treatment, *CONSENSUS (Social sciences), *GENOMICS, *BRCA genes, *DISEASE management, *QUESTIONNAIRES, *DESCRIPTIVE statistics, *PATIENT care, *METASTASIS, *ATTITUDES of medical personnel, *QUALITY assurance, *HEALTH care teams, *GENETIC testing
Abstract

INTRODUCTION: The management of prostate cancer (PCa) is rapidly evolving. Treatment and diagnostic options grow annually, however, high-level evidence for the use of new therapeutics and diagnostics is lacking. In November 2022, the Genitourinary Research Consortium held its 3rd Canadian Consensus Forum (CCF3) to provide guidance on key controversial areas for management of PCa. METHODS: A steering committee of eight multidisciplinary physicians identified topics for discussion and adapted questions from the Advanced Prostate Cancer Consensus Conference 2022 for CCF3. Questions focused on management of metastatic castration-sensitive prostate cancer (mCSPC); use of novel imaging, germline testing, and genomic profiling; and areas of non-consensus from CCF2. Fifty-eight questions were voted on during a live forum, with threshold for "consensus agreement" set at 75%. RESULTS: The voting panel consisted of 26 physicians: 13 urologists/uro-oncologists, nine medical oncologists, and four radiation oncologists. Consensus was reached for 32 of 58 questions (one ad-hoc). Consensus was seen in the use of local treatment, to not use metastasis-directed therapy for low-volume mCSPC, and to use triplet therapy for synchronous high-volume mCSPC (low prostate-specific antigen). Consensus was also reached on sufficiency of conventional imaging to manage disease, use of germline testing and genomic profiling for metastatic disease, and poly (ADP-ribose) polymerase (PARP) inhibitors for BRCA-positive prostate cancer. CONCLUSIONS: CCF3 identified consensus agreement and provides guidance on >30 practice scenarios related to management of PCa and nine areas of controversy, which represent opportunities for research and education to improve patient care. Consensus initiatives provide valuable guidance on areas of controversy as clinicians await high-level evidence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Addressing controversial areas in the management of advanced prostate cancer in Canada

Author

Saad, Fred, primary, Hotte, Sebastien J., additional, Noonan, Krista, additional, Malone, Shawn, additional, Morash, Christopher, additional, Niazi, Tamim, additional, Rendon, Ricardo A., additional, Shayegan, Bobby, additional, Basappa, Naveen S., additional, Cagiannos, Ilias, additional, Danielson, Brita, additional, Delouya, Guila, additional, Fernandes, Ricardo, additional, Ferrario, Cristiano, additional, Finelli, Antonio, additional, Gotto, Geoffrey T., additional, Hamilton, Robert J., additional, Izard, Jason P., additional, Kapoor, Anil, additional, Lalani, Aly-Khan, additional, Lavallée, Luke T., additional, Ong, Michael, additional, Pouliot, Frédéric, additional, So, Alan I., additional, Yip, Steven, additional, and Chi, Kim N., additional

Published
2023
Full Text
View/download PDF

15. Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma

Author

Petrylak, Daniel P., primary, Eigl, Bernhard J., additional, George, Saby, additional, Heath, Elisabeth I., additional, Hotte, Sebastien J., additional, Chism, David D., additional, Nabell, Lisle M., additional, Picus, Joel, additional, Cheng, Susanna Y., additional, Appleman, Leonard J., additional, Sonpavde, Guru P., additional, Morgans, Alicia K., additional, Pourhosseini, Pourya, additional, Wu, Ruishan, additional, Standley, Laura, additional, Croitoru, Ruslan, additional, and Yu, Evan Y., additional

Published
2023
Full Text
View/download PDF

16. A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205

Author

Hotte, Sebastien J., Chi, Kim N., Joshua, Anthony M., Tu, Donsheng, Macfarlane, Robyn J., Gregg, Rirchard W., Ruether, Joseph D., Basappa, Naveen S., Finch, Daygen, Salim, Muhammad, Winquist, Eric W., Torri, Vamsee, North, Scott, Kollmannsberger, Christian, Ellard, Susan L., Eigl, Bernard J., Tinker, Anna, Allan, Alison L., Beja, Kevin, Annala, Matti, Powers, Jean, Wyatt, Alexander W., and Seymour, Lesley

Published
2019
Full Text
View/download PDF

17. 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice.

Author

Chi, Kim N., Yip, Steven M., Bauman, Glenn, Probst, Stephan, Emmenegger, Urban, Kollmannsberger, Christian K., Martineau, Patrick, Niazi, Tamim, Pouliot, Frédéric, Rendon, Ricardo, Hotte, Sebastien J., Laidley, David T., and Saad, Fred

Subjects
CASTRATION-resistant prostate cancer, ANDROGEN receptors, ADVERSE health care events
Abstract

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistant prostate cancer (mCRPC). As this treatment represents a new therapeutic class, guidance regarding how to integrate it into clinical practice is needed. This article aims to review the evidence from prospective phase 2 and 3 clinical trials and meta-analyses of observational studies on the use of 177Lu-PSMA-617 in prostate cancer and discuss how Canadian clinicians might best apply these data in practice. The selection of appropriate patients, the practicalities of treatment administration, including necessary facilities for treatment procedures, the assessment of treatment response, and the management of adverse events are considered. Survival benefits were observed in clinical trials of 177Lu-PSMA-617 in patients with progressive, PSMA-positive mCRPC who were pretreated with androgen receptor pathway inhibitors and taxanes, as well as in taxane-naïve patients. However, the results of ongoing trials are awaited to clarify questions regarding the optimal sequencing of 177Lu-PSMA-617 with other therapies, as well as the implications of predictive biomarkers, personalized dosimetry, and combinations with other therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.

Author

Kyriakopoulos, Christos, Chatta, Gurkamal S., Laccetti, Andrew Leonard, Iannotti, Nicholas, Sokolova, Alexandra, Hotte, Sebastien J., Tutrone, Ronald F., Markowski, Mark Christopher, Nordquist, Luke T., Pili, Roberto, Saad, Fred, Zhang, Jingsong, Villaluna, Karen, Younginger, Brett, Le Moigne, Ronan, and Cesano, Alessandra

Published
2024
Full Text
View/download PDF

19. Genetic testing practices among specialist physicians who treat prostate cancer

Author

Yip, Steven M., primary, Morash, Christopher, additional, Kolinsky, Michael P., additional, Kapoor, Anil, additional, Ong, Michael, additional, Selvarajah, Shamini, additional, Nuk, Jennifer, additional, Compton, Katie, additional, Pouliot, Frederic, additional, Lavallée, Luke T., additional, Khalaf, Daniel J., additional, Hamilton, Robert J., additional, Gotto, Geoffrey T., additional, Rendon, Ricardo A., additional, Antebi, Elie, additional, Hotte, Sebastien J., additional, Malone, Shawn, additional, Chi, Kim N., additional, Drachenberg, Darrel E., additional, Saad, Fred, additional, Chan, Jonathan, additional, Ferrario, Cristiano, additional, Ko, Jenny, additional, Shayegan, Bobby, additional, Parimi, Sunil, additional, So, Alan I., additional, Feifer, Andrew, additional, Jansz, Kenneth, additional, Finch, Daygen, additional, Chin, Joseph L., additional, Osborne, Brendan, additional, Ho, Kai Fai, additional, Demanga Galamo, Corine, additional, Zardan, Anousheh, additional, and Niazi, Tamim, additional

Published
2023
Full Text
View/download PDF

22. The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey

Author

Al-Ezzi, Esmail M., primary, Zahralliyali, Amer, additional, Hansen, Aaron R., additional, Hamilton, Robert J., additional, Crump, Michael, additional, Kuruvilla, John, additional, Wood, Lori, additional, Nappi, Lucia, additional, Kollmannsberger, Christian K., additional, North, Scott A., additional, Winquist, Eric, additional, Soulières, Denis, additional, Hotte, Sebastien J., additional, and Jiang, Di Maria, additional

Published
2023
Full Text
View/download PDF

23. Supplementary Tables S1-S2 from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

Author

Matsubara, Nobuaki, primary, de Bono, Johann, primary, Olmos, David, primary, Procopio, Giuseppe, primary, Kawakami, Satoru, primary, Ürün, Yüksel, primary, van Alphen, Robbert, primary, Flechon, Aude, primary, Carducci, Michael A., primary, Choi, Young Deuk, primary, Hotte, Sebastien J., primary, Korbenfeld, Ernesto, primary, Kramer, Gero, primary, Agarwal, Neeraj, primary, Chi, Kim N., primary, Dearden, Simon, primary, Gresty, Christopher, primary, Kang, Jinyu, primary, Poehlein, Christian, primary, Harrington, Elizabeth A., primary, and Hussain, Maha, primary

Published
2023
Full Text
View/download PDF

24. Data from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

Author

Matsubara, Nobuaki, primary, de Bono, Johann, primary, Olmos, David, primary, Procopio, Giuseppe, primary, Kawakami, Satoru, primary, Ürün, Yüksel, primary, van Alphen, Robbert, primary, Flechon, Aude, primary, Carducci, Michael A., primary, Choi, Young Deuk, primary, Hotte, Sebastien J., primary, Korbenfeld, Ernesto, primary, Kramer, Gero, primary, Agarwal, Neeraj, primary, Chi, Kim N., primary, Dearden, Simon, primary, Gresty, Christopher, primary, Kang, Jinyu, primary, Poehlein, Christian, primary, Harrington, Elizabeth A., primary, and Hussain, Maha, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Data from Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Author

Stathis, Anastasios, primary, Hotte, Sebastien J., primary, Chen, Eric X., primary, Hirte, Holger W., primary, Oza, Amit M., primary, Moretto, Patricia, primary, Webster, Sheila, primary, Laughlin, Anne, primary, Stayner, Lee-Anne, primary, McGill, Shauna, primary, Wang, Lisa, primary, Zhang, Wen-jiang, primary, Espinoza-Delgado, Igor, primary, Holleran, Julianne L., primary, Egorin, Merrill J., primary, and Siu, Lillian L., primary

Published
2023
Full Text
View/download PDF

27. First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.

Author

Mucci, Lorelei A, primary, Vinson, Jake, additional, Gerke, Travis A., additional, Hyslop, Terry, additional, Howard, Lauren, additional, Dreicer, Robert, additional, Rathkopf, Dana E., additional, Chi, Kim N., additional, Esteban, Emilio, additional, Enting, Deborah, additional, Bjartell, Anders, additional, Tagawa, Scott T., additional, Nanus, David M., additional, Ong, Michael, additional, Barata, Pedro C., additional, Hotte, Sebastien J., additional, Grant, Marie, additional, Villanti, Paul, additional, Kantoff, Philip W., additional, and George, Daniel J., additional

Published
2023
Full Text
View/download PDF

28. Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Author

Gotto, Geoffrey T., primary, Yip, Steven M., additional, Shayegan, Bobby, additional, O'Sullivan, Dylan E., additional, Wallis, Christopher J.D., additional, Basappa, Naveen S., additional, Cagiannos, Ilias, additional, Hamilton, Robert James, additional, Ferrario, Cristiano, additional, Fernandes, Ricardo, additional, Danielson, Brita, additional, Saad, Fred, additional, Hotte, Sebastien J., additional, Brenner, Darren R., additional, Cheung, Winson Y., additional, Boyne, Devon J., additional, Chan, Katherine, additional, Osborne, Brendan, additional, Zardan, Anousheh, additional, and Malone, Shawn, additional

Published
2023
Full Text
View/download PDF

29. Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.

Author

Kwan, Edmond Michael, primary, Rushton, Moira Katherine, additional, Tu, Wilson, additional, Hotte, Sebastien J., additional, Mukherjee, Som D., additional, Ong, Michael, additional, Kolinsky, Michael Paul, additional, Hamilou, Zineb, additional, Winquist, Eric, additional, Ferrario, Cristiano, additional, Macfarlane, Robyn Jane, additional, Saad, Fred, additional, Salim, Muhammad, additional, Jiang, Di Maria, additional, Tu, Dongsheng, additional, Hutchenreuther, James, additional, Annala, Matti, additional, Seymour, Lesley, additional, Chi, Kim N., additional, and Wyatt, Alexander William, additional

Published
2023
Full Text
View/download PDF

30. Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

Author

Lalani, Aly-Khan A., primary, Swaminath, Anand, additional, Pond, Gregory Russell, additional, Morgan, Scott C., additional, Azad, Arun, additional, Chu, William, additional, Kapoor, Anil, additional, Bonert, Michael, additional, Bramson, Jonathan L., additional, Surette, Michael G., additional, Bosse, Dominick, additional, Siva, Shankar, additional, Bjarnason, Georg A., additional, Gopaul, Darin, additional, Basappa, Naveen S., additional, Wright, Jim, additional, and Hotte, Sebastien J., additional

Published
2023
Full Text
View/download PDF

33. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial

Author

Mesía, Ricard, Henke, Michael, Fortin, Andre, Minn, Heikki, Yunes Ancona, Alejandro Cesar, Cmelak, Anthony, Markowitz, Avi B, Hotte, Sebastien J, Singh, Simron, Chan, Anthony T C, Merlano, Marco C, Skladowski, Krzysztof, Zhang, Alicia, Oliner, Kelly S, VanderWalde, Ari, and Giralt, Jordi

Published
2015
Full Text
View/download PDF

35. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

Author

Choueiri, Toni K, primary, Kluger, Harriet, additional, George, Saby, additional, Tykodi, Scott S, additional, Kuzel, Timothy M, additional, Perets, Ruth, additional, Nair, Suresh, additional, Procopio, Giuseppe, additional, Carducci, Michael A, additional, Castonguay, Vincent, additional, Folefac, Edmund, additional, Lee, Chung-Han, additional, Hotte, Sebastien J., additional, Miller,, Wilson H, additional, Saggi, Shruti Shally, additional, Lee, Chung-Wei, additional, Desilva, Heshani, additional, Bhagavatheeswaran, Prabhu, additional, Motzer, Robert J, additional, and Escudier, Bernard, additional

Published
2022
Full Text
View/download PDF

36. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

Author

Matsubara, Nobuaki, primary, de Bono, Johann, additional, Olmos, David, additional, Procopio, Giuseppe, additional, Kawakami, Satoru, additional, Ürün, Yüksel, additional, van Alphen, Robbert, additional, Flechon, Aude, additional, Carducci, Michael A., additional, Choi, Young Deuk, additional, Hotte, Sebastien J., additional, Korbenfeld, Ernesto, additional, Kramer, Gero, additional, Agarwal, Neeraj, additional, Chi, Kim N., additional, Dearden, Simon, additional, Gresty, Christopher, additional, Kang, Jinyu, additional, Poehlein, Christian, additional, Harrington, Elizabeth A., additional, and Hussain, Maha, additional

Published
2022
Full Text
View/download PDF

38. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial

Author

Sternberg, Cora N, Castellano, Daniel, Daugaard, Gedske, Géczi, Lajos, Hotte, Sebastien J, Mainwaring, Paul N, Saad, Fred, Souza, Ciro, Tay, Miah H, Garrido, José M Tello, Galli, Luca, Londhe, Anil, De Porre, Peter, Goon, Betty, Lee, Emma, McGowan, Tracy, Naini, Vahid, Todd, Mary B, Molina, Arturo, and George, Daniel J

Published
2014
Full Text
View/download PDF

39. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy

Author

Graham, Jeffrey, primary, Wells, John Connor, additional, Dudani, Shaan, additional, Gan, Chun L., additional, Donskov, Frede, additional, Lee, Jae-lyun, additional, Kollmannsberger, Christian K., additional, Meza, Luis, additional, Beuselinck, Benoit, additional, Hansen, Aaron, additional, North, Scott A., additional, Bjarnason, Georg A., additional, Sayegh, Nicolas, additional, Kanesvaran, Ravindran, additional, Wood, Lori A., additional, Hotte, Sebastien J., additional, McKay, Rana R., additional, Choueiri, Toni K., additional, and Heng, Daniel Y.C., additional

Published
2022
Full Text
View/download PDF

44. CCTG PR21: A randomized phase II study of [177lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).

Author

Chi, Kim N., primary, Saad, Fred, additional, Parulekar, Wendy R., additional, Emmenegger, Urban, additional, Hotte, Sebastien J., additional, Pouliot, Frederic, additional, Bauman, Glenn, additional, Zukotynski, Katherine A., additional, Peacock, Stuart, additional, Wyatt, Alexander William, additional, Beauregard, Jean-Mathieu, additional, Lee, Justin, additional, Uribe, Carlos, additional, Dellar, Conor, additional, Ding, Keyue, additional, and Benard, Francois, additional

Published
2022
Full Text
View/download PDF

45. The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma.

Author

Kuruvilla, Sara, primary, Meyers, Brandon M., additional, Parker, Christina, additional, Nichols, Anthony C., additional, Smoragiewicz, Martin, additional, Hotte, Sebastien J., additional, Pond, Gregory Russell, additional, Louie, Alexander V., additional, Stewart, Paul, additional, Black, Morgan, additional, Carreau, Caitlin, additional, Lee, Justin, additional, Read, Nancy, additional, Sathya, Jinka, additional, Lang, Pencilla, additional, Kevin, Fung, additional, Venkatesan, Varagur, additional, Kim, Richard B., additional, Palma, David A., additional, and Winquist, Eric, additional

Published
2022
Full Text
View/download PDF

47. Patterns of care for non‐metastatic castration‐resistant prostate cancer: A population‐based study

Author

Malone, Shawn, primary, Wallis, Christopher J. D., additional, Lee‐Ying, Richard, additional, Basappa, Naveen S., additional, Cagiannos, Ilias, additional, Hamilton, Robert J., additional, Fernandes, Ricardo, additional, Ferrario, Cristiano, additional, Gotto, Geoffrey T., additional, Morgan, Scott C., additional, Morash, Christopher, additional, Niazi, Tamim, additional, Noonan, Krista L., additional, Rendon, Ricardo, additional, Hotte, Sebastien J., additional, Saad, Fred, additional, Zardan, Anousheh, additional, Osborne, Brendan, additional, Chan, Katherine F. Y., additional, and Shayegan, Bobby, additional

Published
2022
Full Text
View/download PDF

49. Additional file 2 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

Author

Voon, Pei Jye, Chen, Eric X., Chen, Helen X., Lockhart, Albert C., Sahebjam, Solmaz, Kelly, Karen, Vaishampayan, Ulka N., Subbiah, Vivek, Razak, Albiruni R., Renouf, Daniel J., Hotte, Sebastien J., Singh, Arti, Bedard, Philippe L., Hansen, Aaron R., Ivy, S. Percy, Wang, Lisa, Stayner, Lee-Anne, Siu, Lillian L., and Spreafico, Anna

Subjects
Data_FILES
Abstract

Additional file 2.

Published
2022
Full Text
View/download PDF

50. Additional file 1 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

Author

Voon, Pei Jye, Chen, Eric X., Chen, Helen X., Lockhart, Albert C., Sahebjam, Solmaz, Kelly, Karen, Vaishampayan, Ulka N., Subbiah, Vivek, Razak, Albiruni R., Renouf, Daniel J., Hotte, Sebastien J., Singh, Arti, Bedard, Philippe L., Hansen, Aaron R., Ivy, S. Percy, Wang, Lisa, Stayner, Lee-Anne, Siu, Lillian L., and Spreafico, Anna

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results